Matt Zuga - Jan 3, 2025 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Signature
/s/ Derek Meisner, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jan 3, 2025
Transactions value $
-$24,367
Form type
4
Date filed
1/7/2025, 07:53 PM
Previous filing
Jun 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Sale -$24.4K -13.2K -6.26% $1.84 198K Jan 3, 2025 Direct F1, F2
transaction ABOS Common Stock Award $0 +66.8K +33.7% $0.00 265K Jan 6, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Employee Stock Option (right to buy) Award $0 +100K $0.00 100K Jan 6, 2025 Common Stock 100K $1.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7700 to $1.9000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Represents an RSU award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
F4 The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.